GlassScriptPhysician profile
Kailey C Hatfield
NPI 1629441746
$3,103.60
in general payments reported to CMS, 2019-2025
27 companies · $800 in 2025
The $800 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $724 · 2022: $493 · 2023: $632 · 2024: $455 · 2025: $800.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,887.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,886.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $470.74 | 2021-2025 | |
| Abbott Laboratories | $356.56 | 2021-2025 | Freestyle Libre |
| Bayer Healthcare Pharmaceuticals INC. | $351.84 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $290.35 | 2021-2025 | Xifaxan, Trulance |
| Astellas Pharma US INC | $155.59 | 2021-2025 | Veozah |
| Lilly USA, LLC | $154.39 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Lundbeck LLC | $143.01 | 2024-2025 | Rexulti, Vyepti |
| Nestle Healthcare Nutrition INC. | $135.80 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $127.03 | 2021-2025 | Rexulti |
| Eisai INC. | $125.00 | 2025 | |
| Stryker Corporation | $118.24 | 2022 | |
| Pfizer INC. | $82.00 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $69.72 | 2022-2025 | Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $69.54 | 2023 | Shingrix, Trelegy Ellipta, Arexvy |
| Bausch Health US, LLC | $60.22 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $56.78 | 2022-2023 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $49.75 | 2021-2023 | |
| Amgen INC. | $44.43 | 2021-2025 | Repatha, Otezla |
| E.R. Squibb & Sons, L.L.C. | $41.01 | 2022-2024 | Eliquis |
| Amarin Pharma, INC. | $36.09 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.54 | 2025 | |
| Vifor Pharma, INC. | $29.50 | 2023 | Veltassa |
| Janssen Pharmaceuticals, INC | $28.69 | 2024 | Spravato |
| Novo Nordisk INC | $26.22 | 2021-2022 | |
| Alkermes, INC. | $19.08 | 2023 | Lybalvi |
| Ibsa Pharma INC. | $18.45 | 2023 | Tirosint, Licart |
| Kowa Pharmaceuticals America, INC. | $13.03 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kailey Hatfield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.